
Journal of Organic Chemistry p. 4873 - 4892 (2019)
Update date:2022-08-04
Topics:
Barnes, David M.
Shekhar, Shashank
Dunn, Travis B.
Barkalow, Jufang H.
Chan, Vincent S.
Franczyk, Thaddeus S.
Haight, Anthony R.
Hengeveld, John E.
Kolaczkowski, Lawrence
Kotecki, Brian J.
Liang, Guangxin
Marek, James C.
McLaughlin, Maureen A.
Montavon, Donna K.
Napier, James J.
Dasabuvir (1) is an HCV polymerase inhibitor which has been developed as a part of a three-component direct-acting antiviral combination therapy. During the course of the development of the synthetic route, two novel coupling reactions were developed. First, the copper-catalyzed coupling of uracil with aryl iodides, employing picolinamide 16 as the ligand, was discovered. Later, the palladium-catalyzed sulfonamidation of aryl nonaflate 33 was developed, promoted by electron-rich palladium complexes, including the novel phosphine ligand, VincePhos (50). This made possible a convergent, highly efficient synthesis of dasabuvir that significantly reduced the mutagenic impurity burden of the process.
View Morewebsite:http://www.greenutra.cn
Contact:0086-411-39553357
Address:No. 7-1-1802, Huizhi Garden,Ocean Square,Dalian, 116033, China
Jiangsu Willing Bio-Tech Co ltd
website:http://www.willingbio.com/
Contact:+86 18796908173
Address:No 18 Guoqiao Road
Contact:+86-838-5655598
Address:Guanghan Nanfeng Industrial Zone
Antaeus Bio-technology Co., LTD(expird)
Contact:021-31252569
Address:shanghai pudong
Contact:+86-15850770348
Address:51 OF XIANGFANGCUN ROAD, Nanjing 210002, China
Doi:10.1021/jo5021618
(2014)Doi:10.1021/ja00436a040
(1976)Doi:10.1248/cpb.24.1033
(1976)Doi:10.1007/BF00510097
()Doi:10.1007/BF00904476
(1976)Doi:10.1016/j.tetlet.2011.08.136
(2011)